Omnicell Inc
F:OC9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Omnicell Inc
F:OC9
|
US |
|
E
|
Equity Residential
SWB:EQR
|
US |
|
D
|
Deep Yellow Ltd
SWB:JMI
|
AU |
Omnicell Inc
Omnicell makes automation and software for hospitals, pharmacies, and health systems that need to store, track, dispense, and replenish medicines and other supplies. Its products include medication cabinets, robotics, packaging systems, and software that help nurses and pharmacists manage drugs more safely and with fewer manual steps. The company sits in the middle of the pharmacy supply chain, where accuracy and inventory control matter a lot. Omnicell sells its systems and then earns ongoing money from software, services, support, and related consumables. Customers pay to install the equipment, connect it to hospital workflows, and keep it running over time. That creates a business that combines upfront hardware sales with recurring service and software revenue. What makes Omnicell’s role different is that it helps control the last mile of medication use inside healthcare facilities. Its tools are designed to reduce waste, improve compliance, and make sure the right drug reaches the right patient at the right time. That makes the company a specialized provider of pharmacy automation rather than a broad medical device maker.
Omnicell makes automation and software for hospitals, pharmacies, and health systems that need to store, track, dispense, and replenish medicines and other supplies. Its products include medication cabinets, robotics, packaging systems, and software that help nurses and pharmacists manage drugs more safely and with fewer manual steps. The company sits in the middle of the pharmacy supply chain, where accuracy and inventory control matter a lot.
Omnicell sells its systems and then earns ongoing money from software, services, support, and related consumables. Customers pay to install the equipment, connect it to hospital workflows, and keep it running over time. That creates a business that combines upfront hardware sales with recurring service and software revenue.
What makes Omnicell’s role different is that it helps control the last mile of medication use inside healthcare facilities. Its tools are designed to reduce waste, improve compliance, and make sure the right drug reaches the right patient at the right time. That makes the company a specialized provider of pharmacy automation rather than a broad medical device maker.
Beat and raise: Omnicell said first-quarter results landed at the high end or above guidance across key metrics, with revenue of $310 million, EBITDA of $45 million, and EPS of $0.55.
Guidance up: Full-year 2026 non-GAAP EBITDA guidance was raised to $153 million to $168 million, and EPS guidance was raised to $1.80 to $2.00, while bookings, ARR, and revenue guidance were unchanged.
Titan XT launch: The company said customer interest in Titan XT is strong, with initial orders booked in Q1 and hardware shipments expected to begin in the second half of 2026.
Competitive demand: Management said health systems are re-evaluating incumbent solutions, and competitive conversion opportunities are building, with more demo equipment being deployed to meet customer interest.
Margin strength: Gross margin improved to 46% from 42% a year ago, helped by product mix and services operating over prior-year software upgrade costs, though management said margins can still fluctuate quarter to quarter.
Retail mix: EnlivenHealth and retail pharmacy remain challenged, but management said large retail players are seeing more stability and rising volumes as they focus on serving demand at lower cost.
